- Home
- ARCT vs EYPT Comparison
ARCT vs EYPT Comparison
Compare ARCT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- EYPT
- Stock Information
- Founded
- ARCT 2013
- EYPT 1987
- Country
- ARCT United States
- EYPT United States
- Employees
- ARCT N/A
- EYPT N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ARCT Health Care
- EYPT Industrials
- Exchange
- ARCT Nasdaq
- EYPT Nasdaq
- Market Cap
- ARCT 487.0M
- EYPT 489.4M
- IPO Year
- ARCT N/A
- EYPT 2005
- Fundamental
- Price
- ARCT $15.88
- EYPT $7.69
- Analyst Decision
- ARCT Strong Buy
- EYPT Strong Buy
- Analyst Count
- ARCT 8
- EYPT 8
- Target Price
- ARCT $61.00
- EYPT $25.71
- AVG Volume (30 Days)
- ARCT 405.9K
- EYPT 665.0K
- Earning Date
- ARCT 03-06-2025
- EYPT 03-06-2025
- Dividend Yield
- ARCT N/A
- EYPT N/A
- EPS Growth
- ARCT N/A
- EYPT N/A
- EPS
- ARCT N/A
- EYPT N/A
- Revenue
- ARCT $160,399,000.00
- EYPT $45,713,000.00
- Revenue This Year
- ARCT $7.33
- EYPT N/A
- Revenue Next Year
- ARCT $4.71
- EYPT N/A
- P/E Ratio
- ARCT N/A
- EYPT N/A
- Revenue Growth
- ARCT N/A
- EYPT 7.50
- 52 Week Low
- ARCT $14.30
- EYPT $6.90
- 52 Week High
- ARCT $45.00
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- ARCT 41.74
- EYPT 41.66
- Support Level
- ARCT $16.03
- EYPT $7.58
- Resistance Level
- ARCT $17.95
- EYPT $8.16
- Average True Range (ATR)
- ARCT 1.29
- EYPT 0.55
- MACD
- ARCT -0.07
- EYPT -0.07
- Stochastic Oscillator
- ARCT 10.29
- EYPT 3.06
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.